The Seventh Circuit Denies Auxilium Lawsuit revival
The Seventh Circuit Denies Auxilium Lawsuit revival
Introduction
The Seventh Circuit denied reviving a Testosterone Replacement Therapy (TRT) lawsuit filed against Auxilium Pharmaceuticals Inc. linked to its drug Testim stating that the District Court prevented the key witness from testifying. The lawsuit filed by a plaintiff was selected for bellwether trial in the multidistrict litigation over alleged deep vein thrombosis (DVT), which he developed in 2013 due to Testim use. The Seventh Circuit asserted that the testimony from the expert witness that the plaintiff decided to use does not match with the facts of his case.
About 6,000 TRT cases are pending in the multidistrict litigation, alleging that the products led to complications like cardiac arrest, stroke, and sudden death. Other defendants in the litigation include Abbott Laboratories Inc., Pharmacia & Upjohn Inc., Pfizer Inc., Endo Pharmaceuticals Inc., Eli Lilly & Co., and Actavis Inc. In a recent announcement, Actavis Incorporation agreed to settle cases over its TRT drug Androderm, accusing them of failing to warn men about side effects.
Comments
Latest News
NC to Get $150M to Boost Opioid Treatment, Recovery
Categories: Opioids
North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid…
SRI Gets FDA OK for High-Dose Naloxone Trial
Categories: Opioids
SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.
The approval was granted under an Investigational New Drug (IND)…
Spokane County to Get $5M in New Opioid Settlement
Categories: Opioids
Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.
The agreement addresses the company’s role in fueling…